| Literature DB >> 34635725 |
Francesca A Ververs1, Suzanne E Engelen2, Roos Nuboer3, Bas Vastert1,4, Cornelis K van der Ent5, Belinda Van't Land1,6, Johan Garssen6,7, Claudia Monaco2, Marianne Boes1,4, Henk S Schipper8,9,10.
Abstract
Invariant Natural Killer T (iNKT) cells respond to the ligation of lipid antigen-CD1d complexes via their T-cell receptor and are implicated in various immunometabolic diseases. We considered that immunometabolic factors might affect iNKT cell function. To this end, we investigated iNKT cell phenotype and function in a cohort of adolescents with chronic disease and immunometabolic abnormalities. We analyzed peripheral blood iNKT cells of adolescents with cystic fibrosis (CF, n = 24), corrected coarctation of the aorta (CoA, n = 25), juvenile idiopathic arthritis (JIA, n = 20), obesity (OB, n = 20), and corrected atrial septal defect (ASD, n = 25) as controls. To study transcriptional differences, we performed RNA sequencing on a subset of obese patients and controls. Finally, we performed standardized co-culture experiments using patient plasma, to investigate the effect of plasma factors on iNKT cell function. We found comparable iNKT cell numbers across patient groups, except for reduced iNKT cell numbers in JIA patients. Upon ex-vivo activation, we observed enhanced IFN-γ/IL-4 cytokine ratios in iNKT cells of obese adolescents versus controls. The Th1-skewed iNKT cell cytokine profile of obese adolescents was not explained by a distinct transcriptional profile of the iNKT cells. Co-culture experiments with patient plasma revealed that across all patient groups, obesity-associated plasma factors including LDL-cholesterol, leptin, and fatty-acid binding protein 4 (FABP4) coincided with higher IFN-γ production, whereas high HDL-cholesterol and insulin sensitivity (QUICKI) coincided with higher IL-4 production. LDL and HDL supplementation in co-culture studies confirmed the effects of lipoproteins on iNKT cell cytokine production. These results suggest that circulating immunometabolic factors such as lipoproteins may be involved in Th1 skewing of the iNKT cell cytokine response in immunometabolic disease.Entities:
Mesh:
Substances:
Year: 2021 PMID: 34635725 PMCID: PMC8505552 DOI: 10.1038/s41598-021-99580-7
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Immunometabolic profiles of adolescents with chronic disease.
| ASD | CF | CoA | JIA | OB | |
|---|---|---|---|---|---|
| N (m/f) | 25 (3/22) | 24 (13/11)** | 25 (17/8)*** | 20 (6/14) | 20 (8/12)* |
| Age (years) | 14.32 (12.66–17.02) | 15.92 (14.18–17.29) | 14.55 (12.73–16.46) | 16.10 (13.82–16.95) | 14.61 (12.99–16.72) |
| BMI (SD) | − 0.15 ± 0.99 | − 0.36 ± 0.93 | 0.19 ± 1.26 | 0.07 ± 1.06 | 3.23 ± 0.33*** |
| Waist-to-hip ratio | 0.76 (0.73–0.79) | 0.84 (0.78–0.89)** | 0.81 (0.77–0.85)* | 0.79 (0.73–0.83) | 0.91 (0.83–0.96)*** |
| Fasting glucose (mmol/L) | 5.00 (4.90- 5.30) | 5.25 (4.83- 5.73) | 5.20 (4.95- 5.30) | 5.10 (4.90- 5.58) | 5.20 (4.93- 5.48) |
| Fasting insulin (mmol/L) | 9.50 (8.05- 14.00) | 7.40 (5.60- 9.80)* | 9.30 (6.40- 10.00) | 9.85 (8.43- 14.00) | 21.00 (13.75- 31.25)*** |
| QUICKI | 0.34 ± 0.02 | 0.35 ± 0.03 | 0.35 ± 0.02 | 0.33 ± 0.02 | 0.30 ± 0.02*** |
| LDL-cholesterol (mmol/L) | 2.10 (1.70–3.10) | 1.50 (1.13–2.08) | 2.40 (1.90–2.70) | 2.25 (1.93–2.50) | 2.49 (2.20–3.10) |
| HDL-cholesterol (mmol/L) | 1.37 ± 0.22 | 1.16 ± 0.22** | 1.27 ± 0.23 | 1.28 ± 0.25 | 1.22 ± 0.21* |
| Triglycerides (mmol/L) | 0.80 (0.50–0.90) | 0.80 (0.60–0.90) | 0.80 (0.65–1.05) | 0.80 (0.60–1.00) | 1.10 (1.00–1.40)*** |
| Hs- CRP (mg/L) | 0.86 (0.38–5.97) | 3.94 (0.92–13.73) | 1.14 (0.42–4.16) | 1.16 (0.45–4.67) | 9.24 (5.58–26.49)** |
| Lymphocytes (× 109/L) | 2.06 ± 0.67 | 2.09 ± 0.68 | 1.87 ± 0.54 | 1.87 ± 0.48 | 2.42 ± 0.69 |
| Monocytes (× 10^9/L) | 0.50 (0.44–0.56) | 0.52 (0.35–0.66) | 0.46 (0.42–0.56) | 0.47 (0.38–50) | 0.48 (0.40–0.56) |
| FABP4 (ng/mL) | 9.61 (8.04–15.73) | 9.69 (5.79–12.65) | 10.57 (5.32–14.13) | 11.77 (8.90–16.03) | 17.64 (11.79–24.96)* |
| Adiponectin (μg/mL) | 131.28 (113.23–142.54) | 122.99 (100.30–151.02) | 105.37 (90.69–133.13)* | 120.12 (93.95–154.39) | 104.60 (78.74–128.95)* |
| Leptin (ng/mL) | 1.08 (0.66–2.14) | 0.50 (0.18–1.06)* | 0.58 (0.13–1.18)* | 1.10 (0.20–2.94) | 8.38 (4.48–10.92)*** |
| Chemerin (ng/mL) | 61.44 (50.81–68.24) | 58.02 (49.75–65.15 | 62.09 (52.23–70.90) | 62.54 (51.52–67.81) | 61.99 (55.73–88.39) |
| MCP-1/CCL-2 (pg/mL) | 37.62 (19.82–60.89) | 39.63 (27.43–71.31) | 50.02 (27.30–58.98) | 37.19 (25.14–62.58) | 31.17 (21.66–42.95) |
| Cathepsin S (ng/mL) | 49.60 ± 1.82 | 53.79 ± 2.16 | 49.67 ± 2.26 | 52.71 ± 2.02 | 46.64 ± 1.99 |
ASD: atrial septal defect, CF: cystic fibrosis, CoA: coarctation of the aorta, JIA: juvenile idiopathic arthritis, OB: obesity, BMI (SD): body mass index standard deviation from the age- and sex matched population mean, QUICKI: quantitative insulin sensitivity check index, LDL: low-density-lipoprotein cholesterol, HDL: high-density-lipoprotein cholesterol, hs-CRP: high sensitivity C-reactive protein, FABP4: fatty acid binding protein 4, MCP-1: monocyte chemoattractant protein 1, CCL-2: C–C motif chemokine ligand 2. All chronic disease groups were compared to healthy ASD controls. * p < 0.05, ** p < 0.01, *** p < 0.001.
Figure 1iNKT cell numbers and phenotype. (A) Circulating iNKT cell numbers presented as percentage of CD3 and as absolute numbers, measured using flow-cytometry of PBMC from patients with CF (n = 17), CoA (n = 22), JIA (n = 18), and obesity (n = 17), and compared with ASD controls (n = 17) using Kruskal–Wallis, followed by post-hoc Mann–Whitney U tests, *p < 0.05. Differences were not significant after multiple testing correction. (B) CD4, CD8 and double negative (DN) iNKT subset division. (C) iNKT cell CD25 expression at T = 0. The observed differences were not significant after multiple testing correction. (D) iNKT cell proliferation and Ki-67 expression after 14 days culture following α-GalCer stimulation. (E) iNKT cell cytokine production measured in supernatant using multiplex immunoassay, after 11 days culture following α-GalCer stimulation of PBMC from patients with CF (n = 24), CoA (n = 24), JIA (n = 18), and obesity (n = 18), compared with ASD controls (n = 25) using Kruskal–Wallis, followed by post-hoc Mann–Whitney U tests, * p < 0.05. Differences remained significant after multiple testing correction.
Figure 2Transcriptional profile of iNKT cells from obese adolescents versus controls. (A) Principal component (PC) analysis of gene expression based on log2-transformed reads per million (RPM) following RNA sequencing, obese adolescents (n = 7) are red and age-and sex matched ASD controls are blue (n = 7). (B) MA plot showing no differential iNKT cell gene expression between obese adolescents and ASD controls (False Discovery Rate-corrected p < 0.01).
Figure 3Plasma factors affect the iNKT cell phenotype. (A) Plasma-induced iNKT cell cytokine production in co-culture measured using ELISA (n = 114), next to THP-1 only (n = 6) and iNKT cells only (n = 4) controls. Plasma was obtained from patients and added to a standardized co-culture set-up using a THP-1 cell line and short-term iNKT cell line. Disease groups were compared using Kruskal–Wallis, followed by post-hoc Mann–Whitney U tests against ASD controls, * p < 0.05. (B) IFN-γ production corresponded with LDL-cholesterol levels in plasma (n = 114, Pearson’s R = 0.222, p = 0.017) but not HDL-cholesterol (n = 114, Pearson’s R = 0.100, p = 0.288). (C) IL-4 cytokine production corresponded with HDL-cholesterol levels in plasma (n = 114, Pearson’s R = 0.206, p = 0.029) but not LDL-cholesterol (n = 114, Pearson’s R = 0.115, p = 0.224). (D) Lipoprotein-induced iNKT cell cytokine production in co-culture. THP-1 macrophages were treated overnight with human LDL or HDL with or without α-GalCer. THP-1 cells were washed before human iNKT cells were added for 24 h (n = 5, for controls n = 4). Co-culture supernatants were harvested and analyzed for human IFN-γ and IL-4 using ELISA, and compared using Mann–Whitney U tests, * p < 0.05, ** p < 0.01. Differences remained significant after multiple testing correction.
Multivariable linear regression identifies immunometabolic predictors.
| Standardized β | Unstandardized β (CI) | P-value | ||
|---|---|---|---|---|
| IFN-γ R2 = 0.17 | ||||
| Sex (m/f) | 0.340 | 459.357 (153.034 to 765.680) | 0.004** | |
| BMI (SD) | − 0.318 | − 133.285 (− 240.260 to − 26.310) | 0.015* | |
| LDL-cholesterol (mmol/L) | 0.260 | 258.203 (71.391 to 445.015) | 0.007** | |
| FABP4 (ln(ng/mL)) | 0.197 | 190.100 (6.387 to 373.813) | 0.043* | |
| Leptin (ln(ng/mL)) | 0.327 | 144.755 (23.026 to 266.484) | 0.020* | |
| IL-4 R2 = 0.11 | ||||
| QUICKI | 0.188 | 2002.211 (− 61.386 to 3.421) | 0.041* | |
| HDL-cholesterol (mmol/L) | 0.208 | 270.409 (84.224 to 3920.198) | 0.023* | |
Multiple linear regression analysis of plasma-induced iNKT cell IFN-γ and IL-4 (n = 114) production in co-culture. Variables entered for backwards selection: Sex, BMI (SD), WHR, fasting glucose, QUICKI, LDL-cholesterol, HDL-cholesterol, triglycerides, hs-CRP, lymphocyte count, monocyte count, FABP4, adiponectin, leptin, chemerin, MCP-1, Cathepsin S. WHR, fasting glucose, triglycerides, hs-CRP, monocyte count, FABP4, leptin, and MCP-1 were first log-transformed. Only significant predictors were reported. *p < 0.05, **p < 0.01.